Table 1.
Baseline characteristics of all study groups.
| Number of patients in each group | GI (up to 45) | GII (45–60) | GIII (>60) | Significance of difference between means & percentages | |
|---|---|---|---|---|---|
| 55 | 33 | 14 | |||
| Recipient age (years) | 38.06±16.31 (range 2–71) | 42.00±16.80 (range 11–71) | 43.71±18.54 (range 14–75) | P=0.35 | |
| Recipient age (years) | Up to 25 | 15 (27.3%) | 6 (18.8%) | 2 (13.3%) | P=0.54 |
| 26–59 | 32 (58.2%) | 22 (68.8%) | 9 (60%) | ||
| >60 | 8 (14.5%) | 4 (12.5%) | 4 (26.7%) | ||
| Recipient gender | Male | 34 (61.8%) | 22 (66.7%) | 8 (57.1%) | P=0.58 |
| Female | 21 (38.2%) | 11 (33.3%) | 6 (42.9%) | ||
| Donor age (years) | 30.6±7.3 | 28.4±6.1 | 25.8±8.9 | P=0.08 | |
| Donor gender | Male | 52 (94.5%) | 27 (84.8%) | 13 (93%) | P=0.11 |
| Female | 3 (5.5%) | 5 (15.6%) | 1 (7) | ||
| Recipient BMI | 24.6±5.2 | 28.4±5.4 | 25.1±5.3 | P≤0.01 | |
| Donor type | LRD | 37 (68.3%) | 26 (81.3%) | 11 (73.3%) | P=0.15 |
| DD | 5 (9.1%) | 5 (15.6%) | 2 (13.3%) | ||
| LURD | 13 (23.6%) | 1 (3.1%) | 2 (13.3%) | ||
| Donor kidney side | Right | 23 (41.8%) | 14 (43.8%) | 7 (46.7%) | P=0.94 |
| Left | 32 (58.2%) | 18 (56.3%) | 8 (53.3%) | ||
| Donor arteries No | Single | 54 (98.2%) | 27 (84.4%) | 5 (33.3%) | P≤0.01 |
| Multiple | 1 (1.8%) | 5 (15.6%) | 10 (66.7%) | ||
| HLA typing | Zero mismatch | 3 (5.7%) | 5 (16.1%) | 1 (7.1%) | P=0.84 |
| Zero match | 1 (1.9%) | 1 (3.2%) | 0 | ||
| Up to 6 mismatches | 33 (62.3%) | 21 (67.7%) | 9 (64.3%) | ||
| 6–11 mismatches | 16 (30.2%) | 4 (12.9%) | 4 (28.6%) | ||
| PRA | Negative | 6 (11.1%) | 3 (9.7%) | 0 | P=0.43 |
| Positive | 48 (88.9%) | 28 (90.3%) | 14 (100%) | ||
| DSA | Negative | 34 (63.0%) | 24 (77.4%) | 11 (78.6%) | P=0.28 |
| Positive | 20 (37.0%) | 7 (22.6%) | 3 (21.4%) | ||
| Cold Ischemia (minute) | 98.25±193.86 | 216.97±371.40 | 194.64±338.61 | ||
| Donor Warm Ischemia(minutes) | 2.83±1.15 | 2.86±1.9 | 4.13±3.1 | P=0.43 | |
| Split function (donor kidney DTPA) | Up to 43% | 6 (11.5%) | 4 (14.8%) | 4 (30.8%) | P=0.25 |
| >43% | 46 (88.5%) | 23 (85.2%) | 9 (69.2%) | ||
| Immunosuppression | Steroid based | 39 (70.9% | 18 (56.3%) | 12 (80.0%) | P=0.20 |
| Steroid sparing | 16 (29.1%) | 14 (43.8%) | 3 (20.0%) | ||
| Follow up (months) | 11.6±10.9 | 11.1±10.3 | 9.1±7.5 | P=0.69 | |